2026-09-16 Product
ABCL635 Phase 2 Data to Be Presented at IMS Congress Company announcement of Phase 2 data presentation for ABCL635 at IMS World Congress on Menopause 2026
D1 +2.3% · +5d +5.5%
2026-08-24 Insider buying
Insider buying $0.6M (1) D1 -6.3% · +5d +8.2%
11 earlier events › 2026-08-15 Company Bull
CFO buys $380k shares above $10 Insider purchase signals confidence
D1 -1.6% · +5d -5.3%
2026-08-14 8-K filing
8-K: Item 1.01, Item 8.01, Item 9.01 D1 +3.7% · +5d -0.5%
2026-08-09 8-K filing
8-K: Item 8.01, Item 9.01 D1 +34.8% · +5d +19.9%
2026-08-06 Earnings Bear
AbCellera Q2 Loss Wider Than Expected, Revenue Plunges Q2 EPS loss of $0.18 vs. $0.17 expected, revenue misses estimates
D1 +10.3% · +5d +68.0%
› 2 waves of this story2026-08-06 Q2 EPS loss of $0.18 missed estimates; revenue of $4.1M down 76% YoY, well below consensus.2026-08-05 Q2 EPS loss of $0.18 vs. $0.17 expected, revenue misses estimates2026-08-05 Earnings
Earnings report D1 -2.8% · +5d +75.0%
2026-08-05 8-K filing
8-K: Item 2.02, Item 7.01, Item 9.01 D1 -2.8% · +5d +75.0%
2026-07-29 8-K filing
8-K: Item 8.01, Item 9.01 D1 +1.9% · +5d +9.8%
2026-07-07 Analyst Bull
Benchmark Upgrades AbCellera to Buy, PT $11 Based on Jazz Pharma deal with $56M upfront
D1 -2.3% · +5d -12.4%
2026-07-07 Analyst
Benchmark upgrades to Buy D1 -2.3% · +5d -12.4%
2026-07-06 8-K filing
8-K: Item 5.02, Item 9.01 D1 -3.0% · +5d -17.2%
2026-06-17 8-K filing
8-K: Item 8.01, Item 9.01 D1 +6.9% · +5d +22.4%
Related — this ticker is not the subject
2026-09-29 Related Company
Strategy proposes daily dividends for STRC The company filed a preliminary proxy and set an Oct. 28 vote on changing payment cadence for four preferred stocks
D1 +6.5% · +5d -11.3%
by direction · sourced
Cases AI-clustered from trusted X authors over 2 weeks; counts are distinct authors. Volume does not predict direction · Not investment advice
be the first
🙂 Post
Facts and opinions separated · All items sourced · Not investment advice
